Scholarlink

<p>Alpha‑synuclein (α‑syn) overexpression models are widely used to unravel the molecular mechanisms of Parkinson’s disease (PD), particularly in light of the dose-dependent transition between its physiological and toxic roles. However, existing systems rely on inducible expression, lack robust dose stratification and comparative cellular contexts. Here, we developed and characterized a panel of stable neuronal cell lines in two human cellular models (SH‑SY5Y neuroblastoma cells and ReNcell VM neural progenitors) overexpressing GFP-tagged wild-type (WT) or A53T mutant α‑syn at low and high overexpression levels. Utilizing this framework, we demonstrated that A53T consistently induces cytotoxicity, oxidative stress and mitochondrial dysfunction in both cell types. In contrast, WT α‑syn had divergent effects depending on the cellular context. In SH‑SY5Y cells, it enhanced mitochondrial function and viability, whereas in ReNcell VM cells, the same protein triggered mitochondrial impairment and elevated oxidative stress. This opposing metabolic response was reflected in increased respiratory activity in SH‑SY5Y cells and a marked decline across WT α‑syn overexpressing ReNcell VM. Importantly, post-translational modification (PTM) landscape of overexpressed WT α‑syn varied dramatically by cell type. ReNcell VM cells exhibited more robust modifications signatures, even in the absence of overt aggregation, which highlights a cell-type-specific PTM landscape that may contribute to differential vulnerability. Our findings underscore a complex interplay between α‑syn dosage, mutational status, cellular environment, and PTM profiles highlighting that neuronal vulnerability in PD is context-dependent. This work establishes a modular in vitro platform for dissecting α‑syn pathology and testing targeted therapeutic strategies grounded in cell-type specificity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Alpha-synuclein overexpression triggers divergent cellular responses and post-translational modifications in SH-SY5Y and ReNcell VM models

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月21日

查看全文
  • Miraj Ud Din Momand,
  • Petra Majerova,
  • Diana Mjartinova,
  • Natalia Maruskinova,
  • Karolina Albertusova,
  • Michael Dobrota,
  • Lubica Fialova,
  • Sara Stefankova,
  • Petar Podlesniy,
  • Muhammad Khalid Muhammadi,
  • Miroslav Balaz,
  • Dominika Fricova

摘要

Alpha‑synuclein (α‑syn) overexpression models are widely used to unravel the molecular mechanisms of Parkinson’s disease (PD), particularly in light of the dose-dependent transition between its physiological and toxic roles. However, existing systems rely on inducible expression, lack robust dose stratification and comparative cellular contexts. Here, we developed and characterized a panel of stable neuronal cell lines in two human cellular models (SH‑SY5Y neuroblastoma cells and ReNcell VM neural progenitors) overexpressing GFP-tagged wild-type (WT) or A53T mutant α‑syn at low and high overexpression levels. Utilizing this framework, we demonstrated that A53T consistently induces cytotoxicity, oxidative stress and mitochondrial dysfunction in both cell types. In contrast, WT α‑syn had divergent effects depending on the cellular context. In SH‑SY5Y cells, it enhanced mitochondrial function and viability, whereas in ReNcell VM cells, the same protein triggered mitochondrial impairment and elevated oxidative stress. This opposing metabolic response was reflected in increased respiratory activity in SH‑SY5Y cells and a marked decline across WT α‑syn overexpressing ReNcell VM. Importantly, post-translational modification (PTM) landscape of overexpressed WT α‑syn varied dramatically by cell type. ReNcell VM cells exhibited more robust modifications signatures, even in the absence of overt aggregation, which highlights a cell-type-specific PTM landscape that may contribute to differential vulnerability. Our findings underscore a complex interplay between α‑syn dosage, mutational status, cellular environment, and PTM profiles highlighting that neuronal vulnerability in PD is context-dependent. This work establishes a modular in vitro platform for dissecting α‑syn pathology and testing targeted therapeutic strategies grounded in cell-type specificity.